Daily Archives: 2012/03/01

Iluvien Update 5: European Approval on the Horizon

2012/03/01
By
Finally, some good news for Alimera (and pSivida). A few days ago, the company announced that it had received a positive outcome to the Decentralized Procedure (DCP) for Iluvien in Europe. Iluvien is now expected to be the first sustained release pharmaceutical in the European Union for the treatment of diabetic macular edema (DME).

The regulatory process will now enter the national phase of the DCP in which the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and each Concerned Member States (CMS) grants its national license. The CMS include Austria, France, (Read more...)

Full Story →

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

2012/03/01
By
Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.’s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow’s treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.

Full Story →

How does nearsightedness develop in children?

2012/03/01
By
Myopia (nearsightedness) develops in children when the lens stops compensating for continued growth of the eye, according to a new study.

Full Story →

Iluvien Marches Forward in Europe

2012/03/01
By
Iluvien, a sustained drug delivery system for the treatment of diabetic macular edema, gets closer to medical use in Europe. This novel treatment for DME remains viable.

Full Story →

Antibiotic Use With Intravitreal Injection Unnecessary

2012/03/01
By
As the number of intravitreal injection procedures increases, so will the incidence of injection-related complications, such as endophthalmitis. Attempting to reduce the rate of postinjection endophthalmitis with prophylactic antibiotics is unnecessary, and might even be counterproductive, according to a study presented here at the World Ophthalmology Congress 2012.

Full Story →

Novel Technique Using Stem Cells Revives Damaged Eye

2012/03/01
By
Treating blindness caused by burns using limbal stem cells harvested from the undamaged eye of the same patient has now become cheaper, easier and safer. Results of a pilot study of the SLET (simplified technique of limbal transplantation) technique conducted at L.V. Prasad Eye Institute on six patients, and published recently in the British Journal of Ophthalmology provides the proof.

Full Story →

Does Early Intervention with Low Vision Aids Reduce Depression in Macular Degeneration Patients?

2012/03/01
By
At the World Ophthalmology Congress held in late February in Abu Dhabi, a small study indicated that early intervention using low-vision aids can greatly reduce the severity of depression related to vision loss in patients with age-related macular degeneration (AMD).

Full Story →

Optogenetic Tool Elucidated

2012/03/01
By
RUB researchers explain channelrhodopsin Controlling nerve cells with the aid of light: this is made possible by optogenetics. It enables, for example, the investigation of neurobiological processes with unprecedented spatial and temporal precision. The key tool of optogenetics is the light-activated protein channelrhodopsin...

Full Story →

Next Generation Ophthalmic Irrigating Solution Posterior Segment Study

2012/03/01
By
Status: Completed, Condition Summary: Eye Diseases

Full Story →

Archives